Human Organ Chip Models Recapitulate Orthotopic Lung Cancer Growth, Therapeutic Responses, and Tumor Dormancy In Vitro.
暂无分享,去创建一个
Donald E Ingber | Alexandra Sontheimer-Phelps | D. Ingber | Christopher S. Chen | Esak Lee | Alexandra Sontheimer-Phelps | O. Levy | Christopher S Chen | Oren Levy | Bryan A. Hassell | Esak Lee | Bryan A Hassell | Girija Goyal | G. Goyal
[1] Zhongyun Dong,et al. Modulation of tumor cell response to chemotherapy by the organ environment , 1994, Cancer and Metastasis Reviews.
[2] L. Tanoue,et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .
[3] N. Annabi,et al. Microengineered cancer-on-a-chip platforms to study the metastatic microenvironment. , 2016, Lab on a chip.
[4] M. Junttila,et al. Translational value of mouse models in oncology drug development , 2015, Nature Medicine.
[5] A. Mammoto,et al. Primary Human Lung Alveolus‐on‐a‐chip Model of Intravascular Thrombosis for Assessment of Therapeutics , 2018, Clinical pharmacology and therapeutics.
[6] Ash A. Alizadeh,et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.
[7] R. Salgia,et al. MET as a possible target for non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Shen Lv,et al. Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation. , 2015, Molecular medicine reports.
[9] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[10] D. Huh,et al. A microengineered pathophysiological model of early-stage breast cancer. , 2015, Lab on a chip.
[11] Anthony Atala,et al. Liver-Tumor Hybrid Organoids for Modeling Tumor Growth and Drug Response In Vitro , 2015, Annals of Biomedical Engineering.
[12] A. Gazdar,et al. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.
[13] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[14] Richard Novak,et al. Matched-Comparative Modeling of Normal and Diseased Human Airway Responses Using a Microengineered Breathing Lung Chip. , 2016, Cell systems.
[15] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[16] M. Tsao,et al. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. , 2015, Translational lung cancer research.
[17] Yong He. Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[18] L. Gianoncelli,et al. Prognostic and predictive value of MET deregulation in non-small cell lung cancer. , 2015, Annals of translational medicine.
[19] Bruce A. Posner,et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells , 2016, Nature Communications.
[20] Luna,et al. Translation of Research Evidence From Animals to Humans , 2006 .
[21] William Pao,et al. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.
[22] D. Ingber,et al. Reconstituting Organ-Level Lung Functions on a Chip , 2010, Science.
[23] Daniel C Leslie,et al. A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice , 2012, Science Translational Medicine.
[24] Leah E. Mechanic,et al. Serum Concentrations of Cytokines and Lung Cancer Survival in African Americans and Caucasians , 2009, Cancer Epidemiology Biomarkers & Prevention.
[25] Katherine N. Elfer,et al. DRAQ5 and Eosin (‘D&E’) as an Analog to Hematoxylin and Eosin for Rapid Fluorescence Histology of Fresh Tissues , 2016, PloS one.
[26] Lihua Huang,et al. Mechanisms of resistance to EGFR tyrosine kinase inhibitors , 2015, Acta pharmaceutica Sinica. B.
[27] F. Ciardiello,et al. Mechanisms of resistance to EGFR-targeted drugs: lung cancer , 2016, ESMO Open.
[28] M. Junttila,et al. Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.
[29] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[30] D. Ingber,et al. Microfluidic organs-on-chips , 2014, Nature Biotechnology.
[31] Thomas C. Ferrante,et al. Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro , 2015, Nature Methods.
[32] M. Beasley,et al. Bronchioloalveolar carcinoma: a review of current concepts and evolving issues. , 2009, Archives of pathology & laboratory medicine.
[33] S. Kudoh,et al. Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIs , 2013, BMC Research Notes.
[34] Aleksandra Markovets,et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.
[35] Peiyong Guan,et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma , 2017, Nature Communications.
[36] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[37] I. Fidler,et al. Orthotopic Models are Necessary to Predict Therapy of Transplantable Tumors in Mice , 1998, Cancer and Metastasis Reviews.